NCT06397313
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06397313
Title RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis (POTAMI-61)
Acronym POTAMI-61
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ryvu Therapeutics SA
Indications
Therapies
Age Groups: adult | senior
Covered Countries POL | ITA


No variant requirements are available.